Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain
Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology
Expansion supports Autonomix's strategy to build long-term value through multi-indication growth
Patient enrollment expected to begin in June 2025
THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received Ethics Committee authorization from the Ministry of Health of the Republic of Uzbekistan to open the clinical trial site for the follow-on phase to its proof-of-concept human clinical trial ('PoC 2') evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. The Company is on track to commence enrollment in June 2025.
'This next phase of our clinical program represents a meaningful advancement for Autonomix,' said Brad Hauser, CEO of Autonomix. 'With Ethics Committee approval, we can now expand our evaluation beyond severe pancreatic cancer pain to include a broader range of visceral cancers. The initial phase of our study in late-stage pancreatic cancer patients delivered promising results, demonstrating significant pain reduction, substantial decreases in opioid use, and meaningful improvements in quality of life. These outcomes reinforce our belief that Autonomix's technology has the potential to address multiple cancer indications with significant unmet need and transform the standard of care. As we build on this momentum, we see a clear opportunity to create long-term value by unlocking a broader set of impactful clinical applications.'
As previously announced, based on the positive results demonstrated in the initial phase of the Company's first-in-human proof-of-concept trial ('PoC 1') in patients with severe pancreatic cancer pain, Autonomix is initiating a follow-on PoC 2 phase in a market expansion opportunity, which has the potential to double the addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers that signal pain through the Celiac Plexus and earlier stage pancreatic cancers with moderate to severe pain.
Autonomix's technology constitutes a platform with the potential to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. The PoC 2 phase will provide a concentrated focus on interventional cancer pain management applications like pancreatic, gall bladder, liver, and bile duct, with potential further expansion in oncology, gastroenterology, and other sectors where the Company has established key opinion leader relationships and emerging preclinical evidence.
For more information about the Company's technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are 'forward-looking statements,' which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the commencement of the PoC 2 phase of the trial. Such forward-looking statements can be identified by the use of words such as 'should,' 'might,' 'may,' 'intends,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'forecasts,' 'expects,' 'plans,' and 'proposes.'
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading 'Risk Factors' and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ('SEC') on May 31, 2024 and in other filings made by us from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media ContactJTC Team, LLCJenene Thomas908.824.0775autonomix@jtcir.comFehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
UMB Financial Corp (UMBF) Q2 2025 Earnings Call Highlights: Strong Loan Growth and Strategic ...
Net Income: $215.4 million, including $13.5 million of acquisition expense. Net Operating Income: $225.4 million or $2.96 per share. Pre-Tax Gain on Investments: $37.7 million, including $29.4 million from Voyager technologies. Net Charge-Offs: $9 million or 13 basis points of average UMB loans. Non-Performing Loans Ratio: Improved by 2 basis points to 26 basis points. CET1 Ratio: 10.39%, a 28 basis point increase from March 31st. Average Loans Growth: Increased 12.7% to $36.4 billion. Average Deposits Growth: Increased 10.7% to $55.6 billion. Net Accretion to Net Interest Income: $42.2 million, with a 27 basis point margin benefit. Assets Under Administration: Grew to $543 billion in fund services, $600 billion in institutional banking. Credit and Debit Card Purchase Volumes: $5.6 billion, driving a 10.4% increase in fees. Operating Expenses: $23.4 million in acquisition-related amortization of intangibles. Preferred Stock Offering: Netting $294 million of Tier 1 capital. Effective Tax Rate: Expected between 19% and 21% for the full year 2025. Warning! GuruFocus has detected 2 Warning Sign with UMBF. Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points UMB Financial Corp (NASDAQ:UMBF) reported strong net income available for common shareholders of $215.4 million, with a significant pre-tax gain of $37.7 million from prior investments. The company achieved a notable 8 basis point expansion in net interest margin and double-digit balance sheet growth. Average loans increased by 12.7% to $36.4 billion, and average deposits rose by 10.7% to $55.6 billion, reflecting solid organic growth. UMB Financial Corp (NASDAQ:UMBF) successfully executed a pilot conversion of Heartland's Minnesota franchise, positioning well for a full conversion in October. The company completed an offering of Series B preferred stock, netting $294 million of Tier 1 capital, enhancing its capital position. Negative Points The company incurred $13.5 million in acquisition expenses, impacting overall net income. Total net charge-offs for the quarter were 17 basis points, with credit card charge-offs being a significant contributor. Operating expenses included $23.4 million in acquisition-related amortization of intangibles, adding to the cost burden. UMB Financial Corp (NASDAQ:UMBF) anticipates third-quarter operating expenses to be slightly higher, driven by merit increases and incentive accruals. The cost of interest-bearing deposits remained flat, but total deposit costs increased, reflecting a mixed shift. Q & A Highlights Q: Can you provide more details on the significant loan growth this quarter and how much of it is attributed to Heartland? A: Mariner Kemper, Chairman and CEO, explained that the loan growth aligns with expectations, with strong production from both Heartland and UMB's legacy team. The quarter saw nearly $2 billion in top-line production, and similar numbers are expected in the next quarter across all categories and regions. Q: How are you managing the alignment of the UMB and Heartland portfolios, and what impact do you expect from payoffs and paydowns? A: Mariner Kemper noted that while some credits may not align with UMB's standards and could be phased out, the overall impact on the balance sheet will be immaterial. The focus is on maintaining a stable payoff level on a combined basis. Q: What is the expected impact of the HSA changes under the new budget bill on long-term growth in deposits and fees? A: Jim Rine, President and CEO of UMB Bank, stated that while the changes could open up eligibility to around 7 million more people, the impact is expected to be marginal. The company is prepared to provide education to newly eligible individuals but does not anticipate a significant windfall. Q: How should we think about expense growth after the integration of Heartland, and what are the expectations for cost savings? A: Ram Shankar, CFO, mentioned that the second phase of cost savings from the Heartland transaction will occur in the fourth and first quarters. The focus is on achieving positive operating leverage, and while specific expense growth rates are not provided, the company aims to achieve all targeted cost savings from the transaction. Q: Can you elaborate on the credit quality at Heartland and the expected path for non-performing loans (NPLs) and net charge-offs (NCOs)? A: Mariner Kemper indicated that NPLs have started to decrease and are expected to continue improving month over month. The company anticipates that charge-offs will remain at or near historical averages for the second half of the year, reflecting confidence in the portfolio's performance. Q: What are you seeing in terms of deposit competition, and how do you expect deposit pricing to evolve? A: Mariner Kemper explained that commercial and institutional deposits are competitive but manageable, with growth possible at institutional money market rates. The consumer segment has seen 1% to 2% growth, and with an expanded branch network and marketing campaigns, UMB expects to capture more consumer deposits. Q: Are there any synergies being realized on the fee revenue side from the HTLF acquisition? A: Mariner Kemper noted that while it's early, there is positive momentum with activities such as credit card sales and mortgage loan applications. The company anticipates more opportunities for corporate trust referrals, with energy levels and pipelines building. Q: How is the Heartland team contributing to balance sheet growth, and is there more capacity for growth? A: Mariner Kemper stated that the Heartland team is just beginning to show its potential, with significant opportunities for future contributions to balance sheet growth. The current results are only the start of what the team can achieve. Q: What is the outlook for the core margin, and how might it be affected by potential Fed rate cuts? A: Ram Shankar explained that the core margin is expected to remain flat in the third quarter. If the Fed cuts rates, it could positively impact the margin as indexed deposits would reprice down. The company is prepared for various scenarios, with fixed asset repricing and other factors providing potential tailwinds. Q: How sustainable is the growth rate in fund services revenue, and what are the prospects for this business line? A: Mariner Kemper expressed confidence in the fund services business, citing strong client service ratings and a robust technology stack. The business benefits from industry disruption and a strong pipeline, with expectations for continued growth driven by both existing client success and new business acquisition. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
5 minutes ago
- Business Wire
GTJAI Successfully Issued the First Publicly Offered Digital Bond of a Chinese Securities Firm
HONG KONG--(BUSINESS WIRE)--Recently, Guotai Junan International Holdings Limited ('GTJAI' or the 'Company', stock code: a company of Guotai Haitong Group, successfully issued its first digitally native bond. This bond, the first digital bond via public offering issued by a Chinese securities firm, was structured as a direct issue, denominated in U.S. dollars, with an amount of no more than US$300 million and a maturity of 3 years. GTJAI acted as left lead joint global coordinator and B&D bank for this issuance, using HSBC Orion 1 as the digital assets platform. Digital bonds are bonds issued using blockchain or decentralized ledger technology (DLT). Their core features are digitization, programmability, and automated execution, which provide greater transparency, reducing costs and risks of settlement failures. In recent years, GTJAI has been making breakthroughs in the field of financial innovation and has actively led the innovative development of digital finance and digital asset business, of which the issue of digital bonds is one of the important initiatives in its deployment of blockchain technology and digitalized finance. In the first half of 2025, the Company submitted its digital bond business plan and received confirmation from the Hong Kong Securities and Futures Commission that it had no further questions on the plan and formally commenced its digital bond issue business. Mr. Zhang Xueming, Chief Financial Officer of GTJAI, said, 'Successfully issuing the first publicly offered digital bond of a Chinese brokerage firm is a testament to our unwavering commitment to financial innovation and a showcase of our professional capabilities in digital finance and contribution to promoting digital assets. This transaction not only enhances operational efficiency and transparency for our clients and investors but also solidifies GTJAI's leadership in pioneering next-generation capital market solutions.' Mr. John O'Neill, Group Head of Digital Assets & Currencies at HSBC, said, 'We are pleased to support GTJAI in the first digital bond issuance by a Chinese brokerage firm in Hong Kong. This transaction demonstrates the capabilities of HSBC Orion to enable both a broader range of digital bonds and issuers. At HSBC, we are committed to building liquidity in digital fixed income, and see more corporations and financial institutions recognising the benefits of digital assets.' The Company will also take this issue as an opportunity to further explore innovative directions such as cross-border digital asset circulation and the digitization of green finance, with a view to providing more digital solutions to the global financial market and contributing to the intelligent transformation and sustainable development of the international financial system. About GTJAI Guotai Junan International ('GTJAI', Stock Code: a company of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI's business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes brokerage, corporate finance, asset management, loans and financing, financial products, which cover three dimensions including individual finance (wealth management), institutional finance (institutional investor services and corporate finance) and investment management. GTJAI has been assigned 'Baa2' and 'BBB+' long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG 'A' rating, Wind ESG 'A' rating and SynTao Green Finance 'A' rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China's capital markets. For more information about GTJAI, please visit
Yahoo
33 minutes ago
- Yahoo
Microsoft, Meta surge after blowout results
LONDON (Reuters) -Shares in artificial intelligence heavyweights Microsoft and Meta Platforms both surged in European trading on Thursday, after blowout quarterly results after-market on Wednesday. Meta shares surged 12.2% in Frankfurt after it forecast quarterly revenue well ahead of Wall Street expectations. Microsoft shares jumped 9%, as surging Azure cloud computing revenue above analysts' expectations, showcasing the growing return on its AI bets. The jump in shares lifted futures on Wall Street, with S&P futures up 1% and futures on the technology-heavy Nasdaq up 1.3%.
